West Cancer Center

« back to all trials

ADVANCED SOLID TUMORS: PHASE 1: LAST LINE: SLITRK6 ADC

Title

Genmab GCT1106-01 Phase 1

Study Title

Site Link

NCT07416123

Malignancy

Bone, Breast, Bladder, Colon, Prostate, Melanoma, RCC, Kidney, Rectal, Lung, NSCLC, SCLC, Soft Tissue, Ovarian, Endometrial, Cervical

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

Last Line

Investigational Agent

GEN1106

Drug Class

SLITRK6 ADC

Dan Vaena, MD

Sponsor

Genmab

Phase

Phase 1

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Have received and progressed on, been ontolerant to, or be inelgibile for all available SOC therapies known to provide a survival or QOL benefit for the specific tumor type
Measurable disease
ECOG PS 0-1
No prior treatment with topo-1 inhibitor based ADC

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Any

Dosing Frequency

Control Agents

Study Protocol

Randomized